Optimization of carvedilol solid lipid nanoparticles: An approach to control the release and enhance the oral bioavailability on rabbits

PloS One
Khalid Mohamed El-Say, Khaled Mohamed Hosny

Abstract

Solid lipid nanoparticles (SLNs) are prospective carriers for oral delivery of poorly soluble drugs with low bioavailability. Therefore, the study aimed at developing carvedilol (CVD) in SLNs to control its release and enhance its bioavailability in the management of hypertension, and cardiac diseases. Box-Behnken design (BBD) was applied to optimize the variables affecting the quality of CVD-SLNs which prepared by homogenization-ultrasonication technique. The concentrations of Percirol (X1), Gelucire (X2), and stearylamine (X3) were chosen as the crucial independent variables. The dependent variables were estimated and analyzed by Statgraphics software to achieve the optimum characteristics of the developed SLNs. The optimized SLNs was evaluated in vitro and in vivo for pharmacokinetic parameters on male New Zealand white rabbits. The results of this study revealed that the CVD-SLNs have a colloidal size of 31.3 nm with zeta potential of 24.25 mV indicating good stability and 91.43% entrapment efficiency. The in vitro release of CVD from the SLNs was best fitted to Hixon-Crowell model that describes the release from the particles with uniform size. The in vivo pharmacokinetics results indicated the prolongation in the mean res...Continue Reading

References

Jun 7, 2000·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·R H MüllerS Gohla
May 9, 2002·International Journal of Pharmaceutics·Roberta CavalliM Fabrizio Saettone
Apr 28, 2004·Advanced Drug Delivery Reviews·S A WissingR H Müller
May 18, 2007·Acta Pharmaceutica : a Quarterly Journal of Croatian Pharmaceutical Society and Slovenian Pharmaceutical Society, Dealing with All Branches of Pharmacy and Allied Sciences·Yuveraj Singh TanwarAnshu Sharma
May 27, 2010·Indian Journal of Pharmaceutical Sciences·S MukherjeeR S Thakur
Apr 7, 2011·International Journal of Nanomedicine·Shuyu XieWenZhong Zhou
Apr 7, 2011·Archives of Pharmacal Research·Raja Hemanth Kumar PotluriPrabhakar Reddy Veerareddy
Aug 13, 2011·Expert Opinion on Drug Delivery·Harshad HardeSanyog Jain
Dec 27, 2011·Journal of Biomedical Nanotechnology·Pratikkumar A Patel, Vandana B Patravale
Jan 13, 2012·Current Drug Discovery Technologies·Rabinarayan Parhi, Padilama Suresh
Feb 21, 2013·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Ketan HippalgaonkarSoumyajit Majumdar
May 27, 2014·Pharmaceutical Development and Technology·Khalid M El-SayMajed Alsawahli
Mar 20, 2015·Pharmaceutical Research·Karin BeckerAndreas Zimmer
Apr 4, 2015·Drug Design, Development and Therapy·Yazeed Hm AljimaeeKhalid M El-Say
Apr 9, 2015·Journal of Liposome Research·Khalid M El-SayAlaa Eldin A Kassem
Jun 26, 2015·International Journal of Nanomedicine·Mutlaq M Al-SubaieBader M Aljaeid
Oct 28, 2015·Advanced Pharmaceutical Bulletin·Neda NaseriParvin Zakeri-Milani
Nov 27, 2015·Journal of Colloid and Interface Science·Kaisa HelttunenMaija Nissinen
Feb 9, 2016·Drug Design, Development and Therapy·Tarek A AhmedKhalid M El-Say

❮ Previous
Next ❯

Methods Mentioned

BETA
dynamic light scattering

Software Mentioned

Kinetica®
Statgraphics
GraphPad
Statgraphics Centurion XV
GraphPad Prism

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.